IntegraGen Logo

IntegraGen

Genomics specialist providing analyses & SaaS for cancer/rare diseases to researchers & labs.

ALINT | PA

Overview

Corporate Details

ISIN(s):
FR0010908723
LEI:
969500CQD8K0BUIGDH55
Country:
France
Address:
5 RUE HENRI DESBRUERES, 91000 EVRY-COURCOURONNES
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

IntegraGen, an OncoDNA group company, is a genomics specialist focused on translating molecular research into clinical practice. The company provides services in cancer genomics and rare genetic diseases, offering interpretable genomic analyses for academic researchers, private laboratories, and life sciences companies. Its core activities include decoding the human genome, identifying genetic biomarkers, and developing and commercializing molecular diagnostic tests. IntegraGen leverages its expertise in high-throughput sequencing and bioinformatics to provide solutions, including proprietary Software-as-a-Service (SaaS) tools designed for the interpretation of large-scale genomic data.

Social Media

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for IntegraGen and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-04-29 18:00
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 351.8 KB
2025-04-29 18:00
Earnings Release
Inside Information / News release on accounts, results
English 356.4 KB
2025-01-15 18:44
Earnings Release
Inside Information / Information on annual revenues
English 214.4 KB
2025-01-15 18:44
Earnings Release
Informations privilégiées / Information sur chiffre d’affaires annuel
French 215.6 KB
2024-10-17 18:29
Earnings Release
Inside Information / News release on accounts, results
English 343.2 KB
2024-10-17 18:29
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 398.7 KB
2024-07-18 18:44
Earnings Release
Inside Information / Other news releases
English 270.7 KB
2024-07-18 18:44
Earnings Release
Informations privilégiées / Autres communiqués
French 268.3 KB
2024-04-18 18:00
Earnings Release
Inside Information / News release on accounts, results
English 372.7 KB
2024-04-18 18:00
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 419.4 KB
2024-01-16 17:45
Earnings Release
Inside Information / Information on annual revenues
English 307.9 KB
2024-01-16 17:45
Earnings Release
Informations privilégiées / Information sur chiffre d’affaires annuel
French 269.3 KB
2023-10-19 18:15
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 332.6 KB
2023-07-13 07:30
Earnings Release
Inside Information / Other news releases
English 204.7 KB
2023-04-24 18:00
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 330.5 KB

Automate Your Workflow. Get a real-time feed of all IntegraGen filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for IntegraGen via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Cantargia Logo
Develops antibody-based drugs targeting IL1RAP for cancer and inflammatory diseases.
Sweden CANTA
Captor Therapeutics S.A. Logo
Develops TPD drugs for oncology and autoimmune disorders, targeting 'undruggable' proteins.
Poland CTX
Developing engineered cellular medicines for regenerative treatment of heart failure.
United Kingdom N/A
Cellectis Logo
Biopharma using gene-editing to create off-the-shelf CAR T-cell cancer therapies.
France ALCLS
Celyad Oncology SA Logo
Clinical-stage biotech developing allogeneic & autologous CAR T-cell therapies for cancer.
Belgium CYAD
Cereno Scientific AB Logo
Clinical-stage biotech developing treatments for rare cardiovascular & pulmonary diseases.
Sweden CRNO
Ceres Power Holdings PLC Logo
Licensing solid oxide tech (SOFC/SOEC) for clean power and green hydrogen to global partners.
United Kingdom CWR
Cessatech A/S Logo
Develops non-invasive pain relief, like a nasal spray, for children.
Denmark CESSA
CHOSA Oncology AB Logo
Develops diagnostics and drug delivery for personalized cancer therapy.
Sweden CHOSA
Cinclus Pharma Holding AB Logo
Late-stage pharma developing a next-gen P-CAB drug for severe GERD and H. pylori.
Sweden CINPHA

Talk to a Data Expert

Have a question? We'll get back to you promptly.